In a major development for millions seeking medical weight-loss options, Novo Nordisk announced that the cash price of its popular GLP-1 medications Wegovy and Ozempic will drop by 30% starting Monday across the United States.
The new monthly price for either drug will now be $349, down from the previous $499, for customers paying without insurance. According to Novo Nordisk, the reduced price will be available at more than 70,000 retail pharmacies, including major outlets such as Walmart and Costco.
The previous cash price for Wegovy was equal to that of a full dose of Zepbound, a competing drug manufactured by Eli Lilly.
Dave Moore, executive vice president at Novo Nordisk, emphasized the company’s effort to increase consumer access, stating:
“As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them.”
Moore noted that the U.S. healthcare system’s complexity — including varying insurance structures and payment methods — has contributed to challenges for patients. He added that the price reduction represents “immediate impact” for those who are uninsured or choose to self-pay.
The price cut is also part of a broader strategy by Novo Nordisk to expand access nationwide. The company says this includes partnerships with telehealth providers and major retailers, efforts to secure broader insurance coverage, and collaboration with U.S. government leaders to reduce the cost burden for individuals living with obesity and type 2 diabetes.
The announcement comes amid rapidly rising public demand for GLP-1 weight-loss and diabetes drugs, with healthcare analysts predicting increased competition — and potentially more price adjustments — within the sector.
